Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
Date:10/29/2009

Gastroenterologie, Hepatologie und Infektiologie, Heinrich-Heine-Universitat Dusseldorf, Dusseldorf, Germany
  • Tuesday, November 3, 2009, 8:00 a.m. - 1:00 p.m., Exhibit Hall C
  • Abstract #1675
  • Efficacy and Safety of Sorafenib in Patients from the Asia-Pacific (AP) Region with Advanced Hepatocellular Carcinoma (HCC): Impact of Prior Transarterial Chemoembolization and Transarterial Embolization (TACE/TAE)

    • Dr. Zhendong Chen, First Affiliated Hospital of Anhui Medical University, Hefei, China
    • Tuesday, November 3, 2009, 8:00 a.m. - 1:00 p.m., Exhibit Hall C
    • Abstract #1694

    "Liver cancer is often diagnosed at an advanced stage when patients tend to be very ill due to pre-existing liver disease," said Todd Yancey, M.D., vice president of clinical development at Onyx. "Onyx and Bayer are committed to evaluating Nexavar in ongoing studies, as will be presented at AASLD, in order to realize the potential benefit the therapy may offer to patients at all stages of the disease and in different treatment settings."

    Nexavar's Differentiated Mechanism

    Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, c-FLT-3 and RET.

    Nexavar is currently approved in more than 80 countries for the treatment of patients with liver cancer and in more than 90 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including breast cancer,
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
    2. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
    3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
    4. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
    5. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
    6. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
    7. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
    8. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
    9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
    10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
    11. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... 2, 2014 ... 2014 präsentierte GARFIELD-AF-Register bietet einen Einblick ... schlaganfallgefährdeten Patienten in der klinischen Praxis ... Daten der nahezu 12.500 im ... unabhängigen Forschungsinitiative zur Untersuchung von Vorhofflimmern, ...
    (Date:9/2/2014)... , September 2, 2014 ... ESC CONGRESS 2014 provide insight into treatment and ... everyday clinical practice --   Data ... Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an ... stroke prevention strategies for atrial fibrillation (AF) patients ...
    (Date:9/2/2014)... Pa. , Sept. 2, 2014 Particle ... adds to its investment in development and manufacturing capabilities ... to Karl Mueller , Particle Sciences, Associate Director ... nice pace adding clean room square footage, equipment and ... our clients.  The company now has over 6000ft 2 ...
    Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2
    (Date:9/2/2014)... Recently, Top 10 Best SEO ... announced that JustHost ( http://www.justhost.com/track/seohosts ) and BlueHost ... “The hosting suppliers we recommend are the best ... hosting features, uptime and server speed with top-level ... Hosting says. “We believe that BlueHost and JustHost ...
    (Date:9/2/2014)... 02, 2014 Friendship Village of ... “This creates a contemporary marketing presence and ... its parent organization, Friendship Senior Options,” said Stephen ... Options. “By changing the logo, we are making ... to seniors and their families.” , Friendship Village ...
    (Date:9/2/2014)... (PRWEB) September 02, 2014 The Wm. Jennings ... fair and public town hall meeting for Veterans and their ... at the outreach fair to provide Veterans with valuable healthcare ... “The town hall will provide a forum where we can ... programs.” , The outreach fair will be held 4:45 p.m. ...
    (Date:9/2/2014)... patients treated with lumpectomy followed by radiation therapy ... mastectomy, according to a large study conducted by ... and the Cancer Prevention Institute of California. , ... with the disease is the first to directly ... surgical interventions: bilateral mastectomy (the removal of both ...
    (Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
    Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2
    ... Reporter , MONDAY, Oct. 25 (HealthDay News) -- Heavy ... developing Alzheimer,s disease or another dementia, a large new study ... in midlife had more than a 100 percent increase in ... Rachel A. Whitmer, a research scientist in Kaiser Permanente,s Division ...
    ... of hormone therapy and radiation have a substantially improved chance ... according to interim results of the largest randomized study of ... at the 52nd Annual Meeting of the American Society for ... men with high-risk prostate cancer in the United States, the ...
    ... Discovery Fund (LSDF) today announced a $5 million grant ... and commercialize new drugs to treat a variety of ... and the sales of drugs in the marketplace, an ... a new non-profit initiative to advance the life sciences ...
    ... sustainably using stem cells derived from trees, a study suggests. ... yew tree whose bark is a natural source of the ... be produced on a commercial scale at low cost, with ... development say the drug treatment currently used on lung, ...
    ... 25 (HealthDay News) -- The arteries of obese children have ... disease, according to a new study. Canadian researchers evaluated ... children. The obese children had abnormal results on an ultrasound ... fast blood flowed through the body. Of special note ...
    ... Oct. 25 (HealthDay News) -- Colorectal cancer screening among ... arrange for the procedure during a mammography visit, a ... inadequate in minority communities in the United States, many ... Memorial Sloan-Kettering Cancer Center in New York City. ...
    Cached Medicine News:Health News: Heavy Smoking Linked to Alzheimer's in Study 2Health News: Heavy Smoking Linked to Alzheimer's in Study 3Health News:Adding radiation to hormone therapy for prostate cancer treatment will increase survival chances 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Plant stem cells could be fruitful source of low-cost cancer drug 2Health News:Arteries of Obese Kids Aging Prematurely: Study 2Health News:Mammogram Visit a Good Time to Arrange Colonoscopy: Study 2
    PowerMed is a billing software....
    MedLook 3.0 is a medical billing software....
    Managed care is a billing and tracking system....
    ... billing program dealing with the clerical aspects ... standard Health Insurance Claim Form, or CMS-1500. ... the internet. This means that you can ... home or work without using a web ...
    Medicine Products: